Clearpoint Neuro Inc

CLPT remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows. Price is currently extended above rising short-term EMAs and in extreme overbought territory, and the late-June bearish exhaustion candle signals waning upside momentum and a likely pullback. Under a Speculative strategy, high asymmetry and defined structure are required, so patience is advised. A pullback toward the 9/21 EMA zone offers a more favorable entry for continuation participation.

• ↑Q2 revenue $10.9M (+18% YoY), signaling sustained product demand.
• ↑New 30k ft² lab (CAL) to expand capacity, targeting >$60M rev.
• ↓H1 operational cash burn of $15M reduced cash reserves to $29.4M.